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Background: The expression of heparanase (HPSE) was associated with postoperative metastatic recurrence in
patients with hepatocellular carcinoma (HCC). The six E-box binding sites in the core promoter of the HPSE gene
suggested that transcription factors of E-box such as upstream stimulatory factor (USF) might regulate the
transcription of the HPSE gene. The aim of our study is to measure the levels of HPSE and USF expression and
investigate the relationship between USF expression and clinicopathological parameters in patients with HCC.
Methods: HPSE, USF1 and USF2 expressions in human HCC cell lines (BEL-7402, HepG2 and HCCLM3) and 15 fresh
human HCC tissue samples were measured by real-time reverse transcriptase-PCR and Western blot analysis. The
normal liver cell line QSG7701 or fresh normal liver tissue samples obtained from 15 additional surgical patients with
hepatic rupture was used as a control. The protein expressions were determined by immunohistochemistry in
paraffin-embedded human HCC tissues and corresponding non-neoplastic tumor surrounding tissues (NTST) of 57
patients.
Results: HPSE, USF1 and USF2 mRNA expressions were increased in HCC cell lines and HCC tissues compared with
normal liver cell line and normal liver tissue. The protein expressions of HPSE, USF1 and USF2 in HCC cell lines and
HCC tissues were also increased. Both USF1 and USF2 expressions were positively correlated with HPSE. USF1 and
USF2 expressions were increased in patients with liver cirrhosis, worse tissue differentiation, advanced HCC stages
and metastatic recurrence.
Conclusions: Increased USF in HCC is associated with HPSE expression. USF might be an important factor in
regulating HPSE expression and act as a novel marker of metastatic recurrence of HCC patients.
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Hepatocellular carcinoma (HCC) is one of the most
common human malignancies and responsible for approxi-
mately 5% of all cancer-related deaths in the world.
Postoperative metastatic recurrence is now known to be
the major cause of death of patients with HCC [1-3].
Metastatic recurrence of HCC is a complex and multi-
step biological process that includes loss of adhesion, mi-
gration, invasion and proliferation of cancer cells. Many
molecules contribute to this process, and some of these
molecules are involved in the mechanical aspects, whereas
others modulate regulatory pathways.* Correspondence: drcxp@qq.com
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unless otherwise stated.Heparanase (HPSE) is an endo-beta-glucuronidase cap-
able of cleaving heparan sulfate. HPSE plays an important
role in extravasation and invasion of tumor cells by cleav-
ing heparan sulfate side chains of heparan sulfate proteo-
glycans on cell surfaces and in extracellular matrices of
basement membrane [4-6]. Previous studies demonstrated
that increased HPSE activity has been detected in various
tumors and was found to correlate with their metastatic
potentials [7-11]. Therefore, HPSE might be a metastatic
marker and predict postoperative metastatic recurrence in
patients with HCC.
To understand the mechanisms of HPSE up-regulation
in tumors, the promoter sequence of HPSE gene was
cloned and the transcription factor binding sites (TFBS)
were subsequently analyzed. Besides various TFBS such as
specificity protein 1 (Sp1), GA-binding protein (GABP)td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the literatures [12-14], the core promoter included six
E-box binding sites which were located at 553-548, 542-
537, 402-397, 286-281, 34-29 and 14-9 bp upstream of
the ATG translation initiation site, respectively [15]. The
results suggested that HPSE gene expression might be
regulated by E-box sites.
The transcription factor upstream stimulatory factor
(USF) was originally identified in HeLa cells by biochem-
ical analysis. Two different genes encode USF which had
been defined as USF1 and USF2 [16]. The human cDNA
cloning of USF1 and USF2 revealed that the USF belongs
to the c-Myc related family of DNA-binding proteins
which have a helix-loop-helix motif and a leucine repeat,
and that USF interacts with its target DNA sequence
(E-box) as a dimer and regulates the transcription of
numerous genes [17].
However, the expression of USF1 and USF2 in HCC is
unknown. The relationship between USF expression and
clinicopathological parameters in patients with HCC
remains to be determined. The aims of our study are to
measure expression of USF in HCC and evaluate the
relationship between USF expression and clinicopatho-
logical parameters in patients with HCC.
Methods
Cell culture
Human normal liver cell line QSG7701, hepatoma car-
cinoma cell line BEL-7402 and HepG2 were purchased
from Cell Bank (National Academy of Science of China,
Shanghai, China). Human highly metastatic liver cancer
cell line HCCLM3 was purchased from Liver Cancer In-
stitute (Zhongshan Hospital, Fudan University, Shanghai,
China).
QSG7701, BEL-7402, HepG2, and HCCLM3 cells were
cultured in DMEM/GlutaMax-1 (Invitrogen, Shanghai,
China) supplemented with 10% FBS (Life Technologies,
Carlsbad, CA, USA), 100 IU/ml penicillin and 100 mg/ml
streptomycin under a 5% CO2 atmosphere at 37°C.
Patients and tissue selection
Fifty-seven patients (44 males and 13 females) under-
went primary surgical resection for HCC in Yijishan
Hospital of Wannan Medical College (Anhui province of
China) between January 2008 and December 2011. The
average age was 55 years (range from 32 to 82 years).
None of the patients had received preoperative therapy.
All primary HCC tissue samples taken from the 57
patients were fixed in 10% formalin, embedded in paraffin,
sectioned consecutively at 4 μm and stained by H&E for
immunohistochemical analysis. The diagnoses were con-
firmed by histopathologic study. Tumor stage was deter-
mined according to the 2002 International Union Against
Cancer TNM classification system. Tumor differentiationwas graded by the Edmondson grading system. The pa-
tients were divided into high-tendency to metastatic re-
currence group (n = 35) and low-tendency to metastatic
recurrence group (n = 22) according to the presence or
absence of the cancer emboli, intrahepatic dissemin-
ation (satellite foci or multiple nodules), disintegrated
tumor capsule and/or lymph node metastasis. The clini-
copathological features of these patients are summa-
rized in Table 1.
Fifteen patients were selected randomly from the 57
cases. The fresh tissue samples were immediately fro-
zen in liquid nitrogen and stored at −80°C after hepa-
tectomy for real-time RT-PCR and Western blotting.
Non-neoplastic tumor surrounding tissues (NTST) speci-
mens were obtained from tissues at a clear distance from
the tumor edge (>1 cm). The fresh normal liver tissue
(NLT) was obtained from 15 additional surgical patients
with hepatic rupture.
Written informed consent was obtained from these pa-
tients. The research protocol followed the ethical guide-
lines of the Declaration of Helsinki and was approved by
the Ethics Committee of the Yijishan Hospital.RNA isolation and real-time RT-PCR analysis
The extraction of total RNA was performed by using
Trizol solution (Invitrogen, Shanghai, China) according
to the manufacturer’s protocols. The RNA was quanti-
fied by using UV spectrophotometry at 260 nm. The
RNA specimens were stored at −80°C until real-time
RT-PCR. Reverse transcription was performed with the
Moloney murine leukemia virus (M-MLV) reverse tran-
scriptase (Promega, Beijing, China), using 2 μg of total
RNA and following the manufacturer’s instructions. The
resulting cDNA was used for real-time quantitative PCR
detection. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as an internal control.
PCR was performed in 25 μl of reaction mixture
containing 100 ng of both sense and antisense primers
(Shanghai Shenggong Company, Shanghai, China), 1 μl
(200 ng) of the cDNA and 12.5 μl SYBR Green PCR
Master Mix (QIAGEN SA). The sequences of the primers
used for PCR are listed in Table 2. Negative controls
(PCR mix without cDNA) were included. The thermal
cycle was 10 minutes at 95°C, and 40 cycles of 95°C for
15 seconds, 55°C for 30 seconds and 72°C for 30 sec-
onds. All assays were evaluated using the Stepone
plus™ real-time PCR system (ABI Company, USA), and
relative expression was calculated by normalizing the
Ct (threshold cycle) of the target gene to the Ct of the
GAPDH housekeeping gene in the same sample. The
experiments, including RNA isolation, reverse transcrip-
tion and real-time quantitative PCR, were performed in
triplicate.
Table 1 Relationship between heparanase (HPSE), upstream stimulatory factor (USF) expression and tumor
characteristics of hepatocellular carcinoma (HCC)
Features n HPSE expression USF1 expression USF2 expression
+ − P + − P + − P
Gender
Male 44 31 13 0.789 25 19 0.850 27 17 0.991
Female 13 8 5 7 6 8 5
Age (years)
< 55 39 28 11 0.850 22 17 0.952 26 13 0.230
≥ 55 18 11 7 10 8 9 9
Tumor diameter (cm)
< 5 18 11 7 0.419 7 11 0.672 8/1 10 0.520
≥ 5 39 28 11 18 21 21 18
AFP (μg/l)
< 400 21 25 11 0.709 13 8 0.503 12 9 0.614
≥ 400 36 14 7 19 17 23 13
HBsAg
Positive 41 30 11 0.217 20 21 0.073 24 17 0.477
Negative 16 9 7 12 4 11 5
Cirrhosis
Yes 21 13 8 0.419 16 5 0.020 17 4 0.021
No 36 26 10 16 20 18 18
Histological differentiation
Well + moderate 38 22 16 0.016 17 21 0.014 19 19 0.012
Poor 19 17 2 15 4 16 3
TNM staging
I + II 31 17 14 0.016 12 19 0.004 15 16 0.028
III + IV 26 22 4 20 6 20 6
Tendency to MR
High 35 29 6 0.003 24 11 0.017 26 9 0.012
Low 22 10 12 8 14 9 13
Postoperative MR
Yes 21 18 3 0.032 14 7 0.035 16 5 0.002
No 30 21 15 12 18 6 24
HPSE expression
Positive 39 27 12 0.003 28 11 0.018
Negative 18 5 13 7 11
Abbreviations: AFP alpha-fetoprotein, HBsAG hepatitis B surface antigen, MR metastatic recurrence.
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Total protein extracts (50 μg) were prepared in sample
buffer containing 20 mM Tris (pH 8.0), 5 mM ethyl-
enediaminetetraacetic acid (EDTA), 0.5% Triton X-100
and complete Mini, EDTA-free protease inhibitors (1:25;
Roche Diagnostics, Mannheim, Germany).
For Western blot analyses, 50 μg of protein were
loaded on a 12% SDS-PAGE gel. The gel was transferred
onto a nitrocellulose transfer membrane (Santa CruzBiotechnology Inc., Santa Cruz, CA, USA) following sep-
aration. Rabbit-anti-HPSE polyclonal antiserum (Jinqiao
biotechnology, Beijing, China; at 1:250 dilution), rabbit-
anti-USF1 polyclonal antiserum (Jinqiao biotechnology,
Beijing, China; at 1:250 dilution), rabbit-anti-USF2 poly-
clonal antiserum (Santa Cruz Biotechnology Inc, Santa
Cruz, USA; at 1:250 dilution) or rabbit-anti-GAPDH
polyclonal antiserum (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA; at 1:10,000 dilution) were used as
Table 2 The sequences of the primers used for PCR
Genes Primers Sequences Size of
product (bp)
HPSE Forward 5′- GCACAAACACTGACAATCCAAG -3′ 101
Reverse 5′- AAAAGGATAGGGTAACCGCAA -3′
USF1 Forward 5′- TTGTCCTGTGCTTGCTTAGAGT -3′ 102
Reverse 5′- CAGGGAAAGGAAGAACCAATG -3′
USF2 Forward 5′- AAATTGATGGAACCAGAACACC -3′ 136
Reverse 5′- TTGTCTGCGTTACAGTCTGGAAT -3′
GAPDH Forward 5′- GTGGTCTCCTCTGACTTCAACA -3′ 136
Reverse 5′- CCACCACCCTGTTGCTGTAG A -3′
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(HRP)-conjugated anti-rabbit IgG (Maixin biotechnol-
ogy, Fujian, China) was used as secondary antibody at
1:10,000 dilution. Protein bands were visualized using
Chemiluminescence Imaging Systems (Cell Signaling
Technology, Danvers, MA, USA). The band intensity
was measured using Quantity One software (Bio-Rad
Laboratories, Hercules, CA, USA). GAPDH was used
as a loading control.
Immunohistochemistry
The HCC tissue sections of 57 patients were deparaffi-
nized and rehydrated. Then, the sections were boiled in
EDTA (1 mmol/l; pH 8.0) for antigen epitope retrieval.
Endogenous peroxidase was blocked with 0.3% hydro-
gen peroxide. After rinsing, slides were incubated with a
mouse polyclonal antibody against HPSE (Jinqiao biotech-
nology, Beijing, China; at 1:500 dilution), USF1 (Jinqiao
biotechnology, Beijing, China; at 1:100 dilution) or USF2
(Santa Cruz Biotechnology Inc., Santa Cruz, USA; at 1:300
dilution) overnight at 4°C. After washing, the slides were
incubated for 30 minutes with HRP-conjugated secondary
antibody (Maixin biotechnology, Fujian, China) at room
temperature. After this incubation, the slides were washed
three times in PBS, and the antibody complexes were
colored with diaminobenzidine (DAB) and then coun-
terstained with hematoxylin. The total HPSE and USF
immunostaining score was calculated as the sum of the
presence of positively stained tumor cells and the stain-
ing intensity. Briefly, the percent positive staining was
scored as 0 (<5%, negative), 1 (5 to 25%, sporadic), 2 (25
to 50%, focal), 3 (50 to 75%, diffuse) or 4 (>75%, diffuse).
The staining intensity was score as 0 (no staining), 1
(weakly stained), 2 (moderately stained) or 3 (strongly
stained). Each specimen was evaluated in eight fields
at × 400 magnification by two independent pathologists
who were unaware of the clinical data. Both percent
positivity of cells and staining intensity were decided
under double-blind condition. The total immunostain-
ing score was calculated with the value of percentpositivity score × staining intensity score, which ranged
from 0 to 12. We defined HPSE, USF1 and USF2 expres-
sion levels as follows: – (score 0 to 1), + (score 2 to 3), ++
(score 4 to 5) and +++ (score > 5). For inconsistent evalua-
tions of individual slides, both observers reviewed the slide
again to obtain a consensus. The patients were divided
into negative expression group (–) and positive expression
group (+, ++ and +++) according to HPSE or USF expres-
sion level.Follow-up
All patients were followed up until December 2012.
The median follow-up time of patients with HCC was
23 months (range from 12 to 60 months). Recurrence
and metastasis were diagnosed by clinical examination,
alpha-fetoprotein (AFP) measurement, liver ultrason-
ography, and computed tomography (CT) scan.Statistical analysis
The results of the descriptive analyses of variables were
reported as mean ± standard deviation (SD). Analysis of
variance and q-test were used to compare the difference
among/between groups. Statistical comparisons for sig-
nificance between different groups were evaluated by the
chi-square test or the Fisher’s exact test. Spearman’s rank
correlation coefficient was used to find the correlation
between two sets of data. All statistical analyses were per-
formed using the SPSS 13.0 software package (SPSS Inc.,
Chicago, IL, USA), and P < 0.05 was considered statisti-
cally significant.Results
Expressions of HPSE, USF1 and USF2 in liver cancer cell
lines and primary HCC
The mean levels of HPSE, USF1 and USF2 mRNA ex-
pression in the three HCC cell lines were significantly
higher than those in normal liver cell line QSG7701
(P < 0.05). Furthermore, USF2 expression in HCCLM3
was significantly higher than those in BEL-7402 and
HepG2 (P < 0.05) (Table 3, Figure 1A). The mean level
of HPSE mRNA expression in HCC tumor tissues was
significantly increased compared with corresponding
NTST and healthy NLT (all P < 0.01, respectively). USF1
and USF2 were also found to be up-regulated in primary
HCC tumor tissues (all P < 0.001, respectively) (Table 3,
Figure 1B).
The levels of HPSE, USF1 and USF2 protein expression
in HCC cell lines were significantly increased (Figure 1C).
The HPSE, USF1 and USF2 protein expression levels were
all increased in HCC tissues compared with corresponding
NTST (Figure 1D).
Table 3 The relative mRNA expression levels of heparanase (HPSE), upstream stimulatory factor (USF)1 and USF2 in
human hepatocellular carcinoma (HCC) cell lines and HCC tissues
Genes Cells Tissues
QSG7701 BEL-7402 HepG2 HCCLM3 NLT NTST HCC
HPSE 0.11 ± 0.06a 1.98 ± 0.13 1.50 ± 0.14 3.01 ± 0.65 0.15 ± 0.08 0.20 ± 0.09 1.75 ± 0.55c
USF1 0.11 ± 0.05a 1.50 ± 0.12 2.34 ± 0.32 2.38 ± 0.23 0.18 ± 0.08 0.22 ± 0.07 1.61 ± 0.45c
USF2 0.10 ± 0.04a 1.70 ± 0.14 10.61 ± 0.92b 16.84 ± 1.66b 0.12 ± 0.09 0.14 ± 0.09 13.92 ± 1.45c
Abbreviations: HCC hepatocellular carcinoma, NLT normal liver tissues, NTST non-neoplastic tumor surrounding tissue. aCompared with BEL-7402, HepG2 and
HCCLM3, P < 0.01; bCompared with BEL-7402, P < 0.01; cCompared with NLT and NTST, P < 0.01.
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HCC
HPSE and USF1 staining were predominantly in the nu-
clei, and the positive signal was brown-yellow granules
in tumor cell nuclei. HPSE and USF1 expressions in
normal hepatocytes of NTST were negative or weakly
positive, while mainly moderately or strongly positive in
HCC cells (Figure 2A-D). There was a significant differ-
ence between the HPSE-positive rate in HCC (39/57)
and that in NTST (5/57, P = 0.000). USF1-positive rate
in HCC (32/57) was significantly higher than that in
NTST (10/57, P = 0.000).
USF2 staining was mainly in the cytoplasm, and the
positive signals were yellow or brown granules in the
cytoplasm of HCC cells, which were distributed in dotsFigure 1 Heparanase (HPSE), upstream stimulatory factor (USF)1 and
(HCC). HPSE, USF1 and USF2 mRNA and protein expressions were significa
specimens assessed with RT-PCR or Western blot. (A) HPSE, USF1 and USF2
QSG7701 was used as a control. *Compared with BEL-7402, HepG2 and HC
liver tissue, human primary HCC tumor tissues and adjacent non-neoplastic
NTST, P < 0.01. (C) HPSE, USF1 and USF2 protein expressions in human HCC
representative human primary HCC tumor tissues (T) and adjacent non-tumand patches. USF2 expression in normal hepatocytes of
NTST was negative, while mainly moderately or strongly
positive in HCC cells (Figure 2E and F). There was a sig-
nificant difference between USF2-positive rate in HCC
(35/57) and that in NTST (9/57, P = 0.000).
Relationship between protein expressions and the
clinicopathological parameters
At the time of the last follow-up, 51 patients eventually
achieved complete follow-up data (89.5%). Twenty-one
patients were found to have postoperative metastasis or
recurrence, and the other 30 were not found to have
metastasis or recurrence.
HPSE protein expression was increased significantly in
patients with worse tissue differentiation, advanced HCCUSF2 mRNA and protein expressions in hepatocellular carcinoma
ntly increased in human HCC cell lines and primary HCC surgical
mRNA expressions in human HCC cell lines. The normal liver cell line
CLM3, P < 0.01. (B) HPSE, USF1 and USF2 mRNA expression in normal
tumor surrounding tissues (NTST) (n = 15). *Compared with NLT and
cell lines; (D) HPSE, USF1 and USF2 protein expressions in four
or liver tissues (N). All experiments were performed three times.
Figure 2 Heparanase (HPSE), upstream stimulatory factor (USF)1 and USF2 protein expression in primary hepatocellular carcinoma
(HCC) tissues. HPSE, USF1 and USF2 protein expressions were significantly increased in primary HCC surgical specimens (n = 57) detected by
immunohistochemistry (original magnification × 400). (A) HPSE-positive expression in HCC tumor tissues. Positive signal of HPSE was brown-yellow
granules in nuclei of HCC cells. (B) HPSE weakly positive expression in corresponding non-neoplastic tumor surrounding tissues (NTST).
(C) USF1-positive expression in HCC tumor tissues. Positive signal of USF1 was brown-yellow granules in nuclei of tumor cells. (D) USF1-negative
expression in NTST. (E) USF2-positive expression in HCC tumor tissues. Positive signal of USF2 was yellow or brown granules in cytoplasm of HCC cells,
which were distributed in dots and patches. (F) USF2-negative expression in NTST. All experiments were performed twice.
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operative metastatic recurrence. HPSE expression was
not associated with sex, age, tumor size, AFP level, hepa-
titis B surface antigen (HBsAg) status and liver cirrhosis
(P > 0.05) (Table 1).
USF1 and USF2 protein expressions were significantly
increased in patients with liver cirrhosis, worse tissue
differentiation, advanced HCC stages, high-tendency to
metastatic recurrence and postoperative metastatic recur-
rence (P < 0.05). In addition, patients with positive HPSE
expression had higher USF1 and USF2 expressions
compared with patients with negative HPSE expression
(P = 0.003, P = 0.018, respectively). Both USF1 and USF2
expressions were not associated with sex, age, tumor
size, AFP level and HBsAg status (P < 0.05) (Table 1).Correlation between HPSE and USF expression
To investigate further the correlation of HPSE and USF
expression in HCC, Spearman’s rank correlation coeffi-
cients were calculated. They were 0.344 (P = 0.009) and
0.363 (P = 0.005), respectively (Table 4). It suggested that
both USF1 and USF2 expressions were positively corre-
lated with HPSE expression.
Discussion
High levels of HPSE mRNA and protein are expressed in
most malignant tumors including HCC and are closely
associated with tumor metastasis, angiogenesis and other
diverse pathological and physiological processes [4-11].
In our previous study, we cloned a 561-bp-long human
HPSE gene core promoter and found it contained six
Table 4 The correlation between heparanase (HPSE) and
upstream stimulatory factor (USF) expression in
hepatocellular carcinoma (HCC) tissues
HPSE USF1 r P USF2 r P
- + ++ +++ - + ++ +++
- 14 2 2 0 0.344 0.009 15 1 1 1 0.363 0.005
+ 2 4 4 3 2 2 4 4
++ 5 2 2 6 3 4 3 5
+++ 4 1 2 4 2 3 3 4
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factors of E-box sites, we speculate that transcription
of the HPSE gene might be regulated by USF in HCC.
USF is a ubiquitously expressed multifunctional tran-
scription factor [16-20], but USF expression and its
role in HCC remain unknown [21,22].
In this study, we found the relative expression levels of
HPSE and USF were significantly increased in the HCC
cell lines and HCC tumor tissues compared with the
normal liver cell line or corresponding NTST. These
results suggest USF might be a biological indicator of
malignant potential of HCC. Highest USF2 expression
level was found in HCCLM3 among all three HCC cell
lines, and HCCLM3 was a human HCC cell line with
high metastatic potential [23]. Therefore, USF2 might
be a potential marker of the metastatic recurrence of
HCC. Furthermore, we found the up-regulations of
USF1 and USF2 mRNA expressions in HCC were incom-
pletely in line with that of HPSE expression. It might be
explained that HPSE transcription was functionally regu-
lated by many transcription factors, and USF was only one
of the transcription factors [12-15].
In our previous study, we found that high HPSE mRNA
expression was associated with worse tissue differenti-
ation, advanced HCC stages, high-tendency to metastatic
recurrence and postoperative metastatic recurrence [7]. In
this study, we found the same results. Furthermore, we
also found that both USF1 and USF2 expressions were sig-
nificantly increased in patients with liver cirrhosis, poor
differentiation, advanced tumor stages, the high-tendency
to metastatic recurrence and postoperative metastatic re-
currence. The close relationship between USF expression
and clinicopathological features predicts that USF might
boost carcinogenesis and metastatic tumor recurrence.
Interestingly, USF expression, rather than HPSE, is as-
sociated with liver cirrhosis. The result suggests that USF
could also play some role in the formation or regulation of
liver cirrhosis.
Additionally, we found USF1 and USF2 expressions
were associated with HPSE expression in HCC, and both
USF1 and USF2 expressions were positively correlated
with HPSE. These results suggest further HPSE expression
in HCC might be regulated by USF. Of course, definiteevidence and concrete mechanism remain to be further
investigated.
Conclusion
USF1 and USF2 expressions are significantly increased
in HCC and positively correlated with HPSE expression.
USF might be an important factor in regulating HPSE ex-
pression and act as a novel marker of metastatic recur-
rence of HCC patients.
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